Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection.

Lucas M, Ulsenheimer A, Pfafferot K, Heeg MH, Gaudieri S, Grüner N, Rauch A, Gerlach JT, Jung MC, Zachoval R, Pape GR, Schraut W, Santantonio T, Nitschko H, Obermeier M, Phillips R, Scriba TJ, Semmo N, Day C, Weber JN, Fidler S, Thimme R, Haberstroh A, Baumert TF, Klenerman P, Diepolder HM.

PLoS One. 2007 Jul 25;2(7):e649.

2.

Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial.

Kronenberger B, Berg T, Herrmann E, Hinrichsen H, Gerlach T, Buggisch P, Spengler U, Goeser T, Nasser S, Wursthorn K, Pape GR, Hopf U, Zeuzem S.

Eur J Gastroenterol Hepatol. 2007 Aug;19(8):639-46.

PMID:
17625432
3.

Characterization of sequence variations in immunodominant regions of the HBV-nucleocapsid protein as a prerequisite for the development of an epitope-based vaccine.

Gruener NH, Gerlach TJ, Ulsenheimer A, Diepolder HM, Wierenga E, Zachoval R, Heeg M, Pape GR, Jung MC.

Vaccine. 2007 Jun 21;25(26):4960-6. Epub 2006 Dec 22.

PMID:
17466417
4.

Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity.

Rollier CS, Paranhos-Baccala G, Verschoor EJ, Verstrepen BE, Drexhage JA, Fagrouch Z, Berland JL, Komurian-Pradel F, Duverger B, Himoudi N, Staib C, Meyr M, Whelan M, Whelan JA, Adams VC, Larrea E, Riezu JI, Lasarte JJ, Bartosch B, Cosset FL, Spaan WJ, Diepolder HM, Pape GR, Sutter G, Inchauspe G, Heeney JL.

Hepatology. 2007 Mar;45(3):602-13. Erratum in: Hepatology. 2007 Jun;45(6):1590. Adams, Victoria A [corrected to Adams, Victoria C]; Lasarte, Juan José [corrected to Lasarte, Juan J].

PMID:
17326154
5.

Transient immunological control during acute hepatitis C virus infection: ex vivo analysis of helper T-cell responses.

Ulsenheimer A, Lucas M, Seth NP, Tilman Gerlach J, Gruener NH, Loughry A, Pape GR, Wucherpfennig KW, Diepolder HM, Klenerman P.

J Viral Hepat. 2006 Oct;13(10):708-14.

6.

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.

Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S.

Gastroenterology. 2006 Apr;130(4):1086-97.

PMID:
16618403
7.

Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins.

Gerlach JT, Ulsenheimer A, Grüner NH, Jung MC, Schraut W, Schirren CA, Heeg M, Scholz S, Witter K, Zahn R, Vogler A, Zachoval R, Pape GR, Diepolder HM.

J Virol. 2005 Oct;79(19):12425-33.

8.

Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection.

Ulsenheimer A, Gerlach JT, Jung MC, Gruener N, Wächtler M, Backmund M, Santantonio T, Schraut W, Heeg MH, Schirren CA, Zachoval R, Pape GR, Diepolder HM.

Hepatology. 2005 Mar;41(3):643-51.

PMID:
15726647
9.

Uptake and presentation of hepatitis C virus-like particles by human dendritic cells.

Barth H, Ulsenheimer A, Pape GR, Diepolder HM, Hoffmann M, Neumann-Haefelin C, Thimme R, Henneke P, Klein R, Paranhos-Baccalà G, Depla E, Liang TJ, Blum HE, Baumert TF.

Blood. 2005 May 1;105(9):3605-14. Epub 2005 Jan 18.

PMID:
15657184
10.

Analysis of a successful HCV-specific CD8+ T cell response in patients with recurrent HCV-infection after orthotopic liver transplantation.

Gruener NH, Jung MC, Ulsenheimer A, Gerlach JT, Zachoval R, Diepolder HM, Baretton G, Schauer R, Pape GR, Schirren CA.

Liver Transpl. 2004 Dec;10(12):1487-96.

11.

Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.

Steinmann D, Barth H, Gissler B, Schürmann P, Adah MI, Gerlach JT, Pape GR, Depla E, Jacobs D, Maertens G, Patel AH, Inchauspé G, Liang TJ, Blum HE, Baumert TF.

J Virol. 2004 Sep;78(17):9030-40.

12.

Antiviral treatment of recurrent hepatitis C virus (HCV) infection after liver transplantation: association of a strong, multispecific, and long-lasting CD4+ T cell response with HCV-elimination.

Schirren CA, Zachoval R, Gerlach JT, Ulsenheimer A, Gruener NH, Diepolder HM, Baretton G, Schraut W, Rau HG, Nitschko H, Pape GR, Jung MC.

J Hepatol. 2003 Sep;39(3):397-404.

PMID:
12927926
13.

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M, Pape GR.

Gastroenterology. 2003 Jul;125(1):80-8.

PMID:
12851873
14.

Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.

Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, Herrmann E, Spengler U, Goeser T, Nasser S, Wursthorn K, Pape GR, Hopf U, Zeuzem S.

Hepatology. 2003 Jun;37(6):1359-67.

PMID:
12774015
15.

[Hepatitis C virus infection 2003 from the point of view of a hepatologist].

Pape GR.

Anaesthesist. 2003 May;52(5):456-8. Review. German. No abstract available.

PMID:
12750831
16.

Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C.

Ulsenheimer A, Gerlach JT, Gruener NH, Jung MC, Schirren CA, Schraut W, Zachoval R, Pape GR, Diepolder HM.

Hepatology. 2003 May;37(5):1189-98.

PMID:
12717401
17.

[21-year-old patient with recurrent diarrhea, weight loss, leg edema and iron deficiency. Gluten sensitive sprue].

Schäfer C, Pape GR, Göke B.

Internist (Berl). 2002 Nov;43(11):1459-63. German. No abstract available.

PMID:
12524925
18.

Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response.

Gruener NH, Jung MC, Ulsenheimer A, Gerlach TJ, Diepolder HM, Schirren CA, Hoffmann R, Wächtler M, Backmund M, Pape GR.

J Hepatol. 2002 Dec;37(6):866-9.

PMID:
12445431
19.

Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers.

Jung MC, Grüner N, Zachoval R, Schraut W, Gerlach T, Diepolder H, Schirren CA, Page M, Bailey J, Birtles E, Whitehead E, Trojan J, Zeuzem S, Pape GR.

Vaccine. 2002 Oct 4;20(29-30):3598-612.

PMID:
12297407
20.

Immunology of hepatitis B infection.

Jung MC, Pape GR.

Lancet Infect Dis. 2002 Jan;2(1):43-50. Review.

PMID:
11892495
21.

Antibody responses against B-cell epitopes of the hypervariable region 1 of hepatitis C virus in self-limiting and chronic human hepatitis C followed-up using consensus peptides.

Isaguliants MG, Widell A, Zhang SM, Sidorchuk A, Levi M, Smirnov VD, Santantonio T, Diepolder HM, Pape GR, Nordenfelt E.

J Med Virol. 2002 Feb;66(2):204-17.

PMID:
11782929
22.
23.

Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus.

Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, Walker B, Sullivan J, Phillips R, Pape GR, Klenerman P.

J Virol. 2001 Jun;75(12):5550-8.

24.

Hepatitis C virus-specific CD4+ T cell response after liver transplantation occurs early, is multispecific, compartmentalizes to the liver, and does not correlate with recurrent disease.

Schirren CA, Jung MC, Worzfeld T, Mamin M, Baretton G, Gerlach JT, Gruener NH, Zachoval R, Houghton M, Rau HG, Pape GR.

J Infect Dis. 2001 Apr 15;183(8):1187-94. Epub 2001 Mar 14.

PMID:
11262200
25.

Chronic diarrhea as a result of intestinal microsposidiosis in a liver transplant recipient.

Goetz M, Eichenlaub S, Pape GR, Hoffmann RM.

Transplantation. 2001 Jan 27;71(2):334-7.

PMID:
11213083
26.

Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial.

Berg T, Hoffmann RM, Teuber G, Leifeld L, Lafrenz M, Baumgarten R, Spengler U, Zeuzem S, Pape GR, Hopf U.

Liver. 2000 Dec;20(6):427-36.

PMID:
11169056
27.

[59-year-old patient with cutaneous lesions and increased iron metabolism parameters].

Mangold E, Diepolder H, Lohse P, Pape GR, Ritter MM.

Internist (Berl). 2000 Oct;41(10):1103-7. German. No abstract available.

PMID:
11084896
28.

CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained.

Lechner F, Gruener NH, Urbani S, Uggeri J, Santantonio T, Kammer AR, Cerny A, Phillips R, Ferrari C, Pape GR, Klenerman P.

Eur J Immunol. 2000 Sep;30(9):2479-87.

29.

Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection.

Cucchiarini M, Kammer AR, Grabscheid B, Diepolder HM, Gerlach TJ, Grüner N, Santantonio T, Reichen J, Pape GR, Cerny A.

Cell Immunol. 2000 Aug 1;203(2):111-23.

PMID:
11006009
30.

Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C.

Baumert TF, Wellnitz S, Aono S, Satoi J, Herion D, Tilman Gerlach J, Pape GR, Lau JY, Hoofnagle JH, Blum HE, Liang TJ.

Hepatology. 2000 Sep;32(3):610-7.

PMID:
10960457
31.

Liver-derived hepatitis C virus (HCV)-specific CD4(+) T cells recognize multiple HCV epitopes and produce interferon gamma.

Schirren CA, Jung MC, Gerlach JT, Worzfeld T, Baretton G, Mamin M, Hubert Gruener N, Houghton M, Pape GR.

Hepatology. 2000 Sep;32(3):597-603.

PMID:
10960455
32.

Liver transplantation in primary biliary cirrhosis: risk assessment and 11-year follow-up.

Rust C, Rau H, Gerbes AL, Pape GR, Haller M, Krämling H, Schildberg FW, Paumgartner G, Beuers U.

Digestion. 2000;62(1):38-43.

PMID:
10899724
33.

Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C.

Grüner NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren CA, Schraut WW, Hoffmann R, Zachoval R, Santantonio T, Cucchiarini M, Cerny A, Pape GR.

J Infect Dis. 2000 May;181(5):1528-36. Epub 2000 May 5.

PMID:
10823750
34.

Role of the specific T-cell response for clearance and control of hepatitis C virus.

Pape GR, Gerlach TJ, Diepolder HM, Grüner N, Jung M, Santantonio T.

J Viral Hepat. 1999 Jul;6 Suppl 1:36-40.

PMID:
10760033
35.

Cytokine profile of liver- and blood-derived nonspecific T cells after liver transplantation: T helper cells type 1/0 lymphokines dominate in recurrent hepatitis C virus infection and rejection.

Schirren CA, Jung M, Worzfeld T, Mamin M, Baretton GB, Gruener NH, Gerlach JT, Diepolder HM, Zachoval R, Pape GR.

Liver Transpl. 2000 Mar;6(2):222-8.

PMID:
10719024
36.

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.

Teuber G, Berg T, Hoffmann RM, Leifeld L, Lafrenz M, Spengler U, Pape GR, Hopf U, Zeuzem S.

Digestion. 2000;61(2):90-7.

PMID:
10705172
37.

Influence of HLA alleles on outcome of hepatitis C virus infection.

Diepolder HM, Scholz S, Pape GR.

Lancet. 1999 Dec 18-25;354(9196):2094-5. No abstract available.

PMID:
10609808
38.

Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C.

Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, Hoffmann R, Schirren CA, Santantonio T, Pape GR.

Gastroenterology. 1999 Oct;117(4):933-41.

PMID:
10500077
39.

Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection.

Jung MC, Hartmann B, Gerlach JT, Diepolder H, Gruber R, Schraut W, Grüner N, Zachoval R, Hoffmann R, Santantonio T, Wächtler M, Pape GR.

Virology. 1999 Sep 1;261(2):165-72.

40.

Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C.

Hoffmann RM, Berg T, Teuber G, Prümmer O, Leifeld L, Jung MC, Spengler U, Zeuzem S, Hopf U, Pape GR.

Z Gastroenterol. 1999 Aug;37(8):715-23.

PMID:
10494606
41.

Differential antigen-processing pathways of the hepatitis B virus e and core proteins.

Diepolder HM, Ries G, Jung MC, Schlicht HJ, Gerlach JT, Gr ner N, Caselmann WH, Pape GR.

Gastroenterology. 1999 Mar;116(3):650-7.

PMID:
10029624
42.

Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C.

Chang KM, Gruener NH, Southwood S, Sidney J, Pape GR, Chisari FV, Sette A.

J Immunol. 1999 Jan 15;162(2):1156-64.

43.

Determination of Hepatitis C Virus-Specific CD4(+) T-Cell Activity in PBMC.

Gerlach JT, Diepolder H, Pape GR.

Methods Mol Med. 1999;19:413-22. doi: 10.1385/0-89603-521-2:413.

PMID:
21374382
44.

A vigorous virus-specific CD4+ T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B.

Diepolder HM, Jung MC, Keller E, Schraut W, Gerlach JT, Grüner N, Zachoval R, Hoffmann RM, Schirren CA, Scholz S, Pape GR.

Clin Exp Immunol. 1998 Aug;113(2):244-51.

45.

Interferon-alpha-induced agranulocytosis in a patient on long-term clozapine therapy.

Hoffmann RM, Ott S, Parhofer KG, Bartl R, Pape GR.

J Hepatol. 1998 Jul;29(1):170. No abstract available.

PMID:
9696507
46.

Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C.

Hoffmann RM, Jung MC, Motz R, Gössl C, Emslander HP, Zachoval R, Pape GR.

J Hepatol. 1998 Jun;28(6):1058-63.

PMID:
9672184
47.

Immunopathogenesis of HCV infection.

Diepolder HM, Hoffmann RM, Gerlach JT, Zachoval R, Jung MC, Pape GR.

Curr Stud Hematol Blood Transfus. 1998;(62):135-51. Review. No abstract available.

PMID:
9507808
48.

Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection.

Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Jung MC, Wierenga EA, Scholz S, Santantonio T, Houghton M, Southwood S, Sette A, Pape GR.

J Virol. 1997 Aug;71(8):6011-9.

49.

Role for CD4 positive T cell response in the pathogenesis of hepatitis B.

Pape GR, Jung MC.

J Hepatol. 1997 May;26(5):1157-8. No abstract available.

PMID:
9186851
50.

Analysis of T cell activation pathways in patients with liver cirrhosis, impaired delayed hypersensitivity and other T cell-dependent functions.

Schirren CA, Jung MC, Zachoval R, Diepolder H, Hoffmann R, Riethmüller G, Pape GR.

Clin Exp Immunol. 1997 Apr;108(1):144-50.

Supplemental Content

Support Center